Clinical trials: Chemotherapy Induced Neutropenia
Chemotherapy Induced Neutropenia
Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia
This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to daily G-CSF in chemotherapy-induced neutropenia.
- Trial name
- PEG-G-CSF (NCT01674855)
- Testing
- PEG-G-CSF, G-CSF
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Dong-A ST Co., Ltd.
Febrile Neutropenia, Cancer
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are receiving filgrastim biosimilar (EP2006) for…
- Conditions
- Febrile Neutropenia, Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- Monitor-GCSF (NCT01459653)
- Where
- 117 sites in Austria, Belgium and 10 more
- Volunteers
- 1,496 people
- Sponsor
- Sandoz
Febrile Neutropenia
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the…
- Trial name
- NCT03104595
- Testing
- EC-18
- Where
- 3 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Enzychem Lifesciences Corporation
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg).
- Trial name
- NCT04345900
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 55 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Breast Cancer Female
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
In the study, subjects will scheduled to undergo four 21-days cycles of chemotherapy treatment. Three group were treated with MW05 300 μg/kg or MW05 500 μg/kg or PEG-rhG-CSF 100 μg/kg on the 3th day of each cycle randomized 1:1:1…
- Trial name
- NCT04554056
- Testing
- MW05, PEG-rhG-CSF
- Where
- China
- Volunteers
- 586 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Lymphoma, Chemotherapy-induced Neutropenia
Danish Elder Lymphoma Patient Hematopoietic Investigation
Every year approximately 300 Danish patients die from lymphoma. The median age at diagnosis is 70 years. Lymphoma can be efficiently treated with chemotherapy, and potentially cured.
- Conditions
- Lymphoma, Chemotherapy-induced Neutropenia, Chemotherapy-Related Leukemia, Chemotherapeutic Toxicity
- Trial name
- DELPHI (NCT05245487)
- Testing
- DNA repair gene mutation analysis
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting
Community-Led Action Research in Oncology: Improving Symptom Management
This study will be conducted at La Liga Contra el Cancer in San Pedro Sula, Honduras. The overall objective of this project is to improve symptom management for patients undergoing chemotherapy in Honduras.
- Conditions
- Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting, Anxiety, Depression
- Trial name
- CLARO (NCT03208816)
- Testing
- symptom management program for chemotherapy patients
- Where
- 2 sites in United States, Honduras
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Neutropenic Fever, Acute Lymphoblastic Leukemia
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
The goal of this clinical trial is To evaluate the benefit of levofloxacin prophylaxis in prolonging the median time to first febrile neutropenia in pediatric ALL patients during induction phase.
- Trial name
- NCT07320534
- Testing
- Levofloxacin
- Where
- Indonesia
- Volunteers
- 49 people
- Sponsor
- Gadjah Mada University
Oncopediatrics, Febrile Neutropenia
Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia
The goal of this clinical trial is to evaluate the feasibility of the study, measured by the acceptability rate of patients to be recruited in a study proposing temperature monitoring at home, by a remote monitoring device or by…
- Trial name
- TELEDOM (NCT06697262)
- Testing
- Remote temperature monitoring device, Home temperature monitoring by a nurse
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Solid Tumor Cancer, Chemotherapy Induced Neutropenia
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
This study is a multi-cohort, open-label, multi-center exploratory clinical research designed to evaluate the efficacy and safety of Efbemalenograstim alfa Injection in preventing neutropenia (reduction in absolute neutrophil…
- Conditions
- Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF
- Trial name
- EF-001 (NCT06649448)
- Testing
- Efbemalenograstim alfa Injection, carboplatin/cisplatin-etoposide, Carboplatin plus Paclitaxel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong Cancer Hospital and Institute
Leukemia, Neutropenia
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Neutropenia, Thrombocytopenia
- Trial name
- NCT00002665
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 83 sites in United States
- Volunteers
- 50 people
- Sponsor
- SWOG Cancer Research Network
Chemotherapy-Induced Neutropenia
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
This study is a Dose block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I clinical trial to assess the safety, tolerability and pharmacokinetics of single-dose and…
- Trial name
- NCT02532712
- Testing
- EC-18
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Enzychem Lifesciences Corporation
Cancer-related Fatigue, Neutropenia, Malignant
PG2 Breast Cancer Evaluation in Adjuvant Medicine Study
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence.
- Trial name
- PG2 BEAM (NCT03314805)
- Testing
- Astragalus polysaccharides 500 mg, EC Chemotherapy
- Where
- 5 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- PhytoHealth Corporation
Cancer in Children/Adolescents, Fever in Neutropenia
Pediatric FN Definition 2012 Bern
STUDY AIMS Based on prospectively collected information on ear temperatures, ANC values, emergency calls and consultations for fever, and on hospitalizations for FN in children and adolescents with cancer to describe the…
- Trial name
- NCT01683370
- Where
- Switzerland
- Volunteers
- 39 people
- Sponsor
- Dr. Roland Ammann
Neutropenia
Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)
The purpose of this study was to analyze the clinical factors associated with the effect of Granulocyte-Colony Stimulating Factor (G-CSF).
- Trial name
- NCT03498248
- Testing
- lenograstim
- Where
- South Korea
- Volunteers
- 155 people
- Sponsor
- DERSHENG SUN
Chemotherapy-induced Neutropenia
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
The objective of this real world study is to confirm the efficacy and saftey of Telpegfilgrastim injection for the prevention of chemotherapy-induced Neutropenia in Patients With Malignant solid tumor.
- Trial name
- NCT07096479
- Testing
- Telpegfilgrastim Injection
- Where
- 2 sites in China
- Volunteers
- 318 people
- Sponsor
- Anhui Provincial Hospital
Breast Cancer, Neutropenia
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
The overall purpose of this study is to assess the dose response, efficacy, and safety of three different dose levels of AVI 014 (granulocyte colony-stimulating factor [G-CSF]) in breast cancer patients at high (>20%) risk for…
- Trial name
- NCT00497809
- Testing
- AVI-014 versus Filgrastim
- Where
- 31 sites in United States, India
- Volunteers
- 189 people
- Sponsor
- AviGenics
Myeloid Leukemia
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
The purpose of this study is to determine if a single dose of pegfilgrastim is able to reduce the time of severe neutropenia in patients receiving induction and consolidation myelosuppressive chemotherapy for de novo acute…
- Trial name
- NCT00114764
- Testing
- filgrastim, pegfilgrastim
- Volunteers
- 84 people
- Sponsor
- Amgen
Chemotherapy-Induced Neutropenia, Myelosuppression
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting the doses and density of chemotherapy that can be tolerated. The degree and duration of neutropenia determine the risk of infection.
- Conditions
- Chemotherapy-Induced Neutropenia, Myelosuppression, Breast Cancer
- Trial name
- MyeloConcept (NCT02692742)
- Testing
- Myelo001
- Where
- 23 sites in Germany
- Volunteers
- 137 people
- Sponsor
- Myelo Therapeutics GmbH